Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in HER2+ Early Breast Cancer (APTneo)
NCT03595592Phase 3Active, not recruiting
- Sponsor
- Michelangelo Foundation
- Start
- Sep 2018
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of atezolizumab in HER2-positive breast cancer, sponsored by Michelangelo Foundation. Started Sep 2018; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03595592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595592.